107 related articles for article (PubMed ID: 20127324)
1. Amylin(1-8) is devoid of anabolic activity in bone.
Ellegaard M; Thorkildsen C; Petersen S; Petersen JS; Jørgensen NR; Just R; Schwarz P; Ramirez MT; Stahlhut M
Calcif Tissue Int; 2010 Mar; 86(3):249-60. PubMed ID: 20127324
[TBL] [Abstract][Full Text] [Related]
2. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism.
Naot D; Cornish J
Bone; 2008 Nov; 43(5):813-8. PubMed ID: 18687416
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of amylin in bone.
Tamura T; Miyaura C; Owan I; Suda T
J Cell Physiol; 1992 Oct; 153(1):6-14. PubMed ID: 1325980
[TBL] [Abstract][Full Text] [Related]
4. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice.
Cornish J; Callon KE; Cooper GJ; Reid IR
Biochem Biophys Res Commun; 1995 Feb; 207(1):133-9. PubMed ID: 7857256
[TBL] [Abstract][Full Text] [Related]
5. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
[TBL] [Abstract][Full Text] [Related]
6. Deletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone.
Lerner UH
J Musculoskelet Neuronal Interact; 2006; 6(1):87-95. PubMed ID: 16675892
[TBL] [Abstract][Full Text] [Related]
7. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors.
Udawela M; Christopoulos G; Tilakaratne N; Christopoulos A; Albiston A; Sexton PM
Mol Pharmacol; 2006 Jun; 69(6):1984-9. PubMed ID: 16531504
[TBL] [Abstract][Full Text] [Related]
8. Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity.
Villa I; Dal Fiume C; Maestroni A; Rubinacci A; Ravasi F; Guidobono F
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E627-33. PubMed ID: 12556355
[TBL] [Abstract][Full Text] [Related]
9. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1.
Cornish J; Grey A; Callon KE; Naot D; Hill BL; Lin CQ; Balchin LM; Reid IR
Biochem Biophys Res Commun; 2004 May; 318(1):240-6. PubMed ID: 15110779
[TBL] [Abstract][Full Text] [Related]
10. Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus.
Haynes JM; Hodgson WC; Cooper ME
Diabetologia; 1997 Mar; 40(3):256-61. PubMed ID: 9084962
[TBL] [Abstract][Full Text] [Related]
11. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo.
Cornish J; Callon KE; Bava U; Watson M; Xu X; Lin JM; Chan VA; Grey AB; Naot D; Buchanan CM; Cooper GJ; Reid IR
Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E117-22. PubMed ID: 16912056
[TBL] [Abstract][Full Text] [Related]
12. Receptor pharmacology.
Young A
Adv Pharmacol; 2005; 52():47-65. PubMed ID: 16492540
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts.
Cornish J; Callon KE; Lin CQ; Xiao CL; Gamble GD; Cooper GJ; Reid IR
J Bone Miner Res; 1999 Aug; 14(8):1302-9. PubMed ID: 10457262
[TBL] [Abstract][Full Text] [Related]
14. A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action.
Sharan K; Mishra JS; Swarnkar G; Siddiqui JA; Khan K; Kumari R; Rawat P; Maurya R; Sanyal S; Chattopadhyay N
J Bone Miner Res; 2011 Sep; 26(9):2096-111. PubMed ID: 21638315
[TBL] [Abstract][Full Text] [Related]
15. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture.
Lane NE; Yao W; Kinney JH; Modin G; Balooch M; Wronski TJ
J Bone Miner Res; 2003 Dec; 18(12):2105-15. PubMed ID: 14672345
[TBL] [Abstract][Full Text] [Related]
16. Functional interaction of G protein-coupled receptors of the adrenomedullin peptide family with accessory receptor-activity-modifying proteins (RAMP).
Born W; Muff R; Fischer JA
Microsc Res Tech; 2002 Apr; 57(1):14-22. PubMed ID: 11921352
[TBL] [Abstract][Full Text] [Related]
17. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function.
Qi T; Christopoulos G; Bailey RJ; Christopoulos A; Sexton PM; Hay DL
Mol Pharmacol; 2008 Oct; 74(4):1059-71. PubMed ID: 18593822
[TBL] [Abstract][Full Text] [Related]
18. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice.
Alles N; Soysa NS; Hayashi J; Khan M; Shimoda A; Shimokawa H; Ritzeler O; Akiyoshi K; Aoki K; Ohya K
Endocrinology; 2010 Oct; 151(10):4626-34. PubMed ID: 20810563
[TBL] [Abstract][Full Text] [Related]
19. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
[TBL] [Abstract][Full Text] [Related]
20. A critical role for the short intracellular C terminus in receptor activity-modifying protein function.
Udawela M; Christopoulos G; Morfis M; Christopoulos A; Ye S; Tilakaratne N; Sexton PM
Mol Pharmacol; 2006 Nov; 70(5):1750-60. PubMed ID: 16912219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
